motherlodetv.net
FSD Pharma (OTCQB:FSDDF) released news this morning that its shares had been approved for listing on the Nasdaq exchange. Big news for a company which, to date, was seen primarily as a Canadian venture. The Nasdaq listing reflects the company’s ongoing commitment to the American pharmaceutical market.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”) has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license is effective as of June 21, 2019.
The Board of Directors of FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), unanimously voted Raza Bokhari, M.D., Executive Co-Chairman of the Board, as permanent Chief Executive Officer. Dr. Bokhari has served as interim CEO of the Company since February.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) would like to congratulate High Tide Inc. (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) (“High Tide”) on the recent announcement from Alberta Gaming, Liquor and Cannabis lifting the moratorium on issuing cannabis licenses and accepting license applications. The announcement is an encouraging sign of steadily improving cannabis supply levels in Alberta and is a positive step for companies like High Tide that have numerous stores ready and waiting to retail cannabis products.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), today announced the appointment of pharmaceutical industry leader, Edward J. Brennan, Jr., M.D., FACS, as President of its biosciences division. Dr. Brennan has more than 25 years’ experience in leadership roles at major pharmaceutical companies and clinical research organizations.
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or “FSD”) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest”), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement. Under the agreement, Solarvest will conduct research using its algal expression technology to develop pharmaceutical-grade cannabinoids. FSD Pharma and Solarvest have made investments into one another and FSD has the option to enter into an exclusive license arrangement over a subset of the project and receive royalty rights over all of the products that result from the project.
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma”, “FSD” or “the Company”) today reported its financial and operational results for the fourth quarter and fiscal year-ended December 31, 2018. These filings are available for review on the Company’s SEDAR profile at www.sedar.com.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that it has entered into a share exchange transaction with Aura Health Inc. (“Aura”). Pursuant to the agreement, FSD acquired 13,562,386 Aura shares valued at $3 million issued from treasury in exchange for 13,181,019 FSD shares issued from treasury valued at $3 million. Aura Health is a Toronto-based cannabis company building an international network of vertically integrated businesses in the medical cannabis industry.
I have an article up about FSD Pharma (C.HUGE) getting its medical sales licence up at Seeking Alpha.
I have an article up at Seeking Alpha on adding value in the cannabis space.